Original articleArthritis presenting during the acute phase of Kawasaki disease
Section snippets
Methods
This single-center retrospective study identified 414 patients diagnosed with Kawasaki disease at The Hospital for Sick Children between January 1997 and December 2002. All patients with possible Kawasaki disease were seen in consultation with a pediatric rheumatologist. Children with suspected Kawasaki disease underwent standardized assessments that included complete clinical examination along with detailed musculoskeletal assessment, laboratory testing, electrocardiograhy, and
Patient Characteristics
A total of 414 children with Kawasaki disease were included in this study, of whom 266 were boys and 148 were girls. The majority of children (84%) had classical Kawasaki disease, and 16% had incomplete Kawasaki disease. The median age at diagnosis was 3.23 years (range, 0.19 to 17.72 years). The demographic and clinical features of these children are summarized in Table I. The children with arthritis and those without arthritis shared the same demographic characteristics and clinical features.
Discussion
Kawasaki disease is a multisystemic disease that includes inflammatory arthritis in its clinical spectrum. The prevalence of arthritis in acute Kawasaki disease in our study was 7.5%, compared with a previously reported prevalence of 31%.9 Similar proportions of patients had oligoarticular and polyarticular involvement, with predominantly large joints affected regardless of the pattern of involvement. However, 88% of affected children experienced a dramatic and rapid resolution of arthritis
References (35)
- et al.
Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome
J Pediatr
(1975) - et al.
Kawasaki syndrome
Pediatr Clin North Am
(1986) - et al.
Serum-soluble interleukin-2 receptor levels in Kawasaki disease
J Pediatr
(1990) - et al.
Spontaneous tumor necrosis factor production in Kawasaki disease
J Pediatr
(1989) - et al.
Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease
Clin Immunol Immunopathol
(1988) - et al.
Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary artery lesions
Clin Immunol Immunopathol
(1990) - et al.
High-dose intravenous gamma globulin for Kawasaki disease
Lancet
(1984) - et al.
Coronary artery dimensions may be misclassified as normal in Kawasaki disease
J Pediatr
(1998) - et al.
A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan
Pediatrics
(1974) - et al.
AHA Scientific Statement. Diagnosis, treatment, and long-term management of Kawasaki diseasea statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Circulation
(2004)
Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in childrenclinical observations of 50 cases
Jpn J Allergol
Clinical aspects of 100 patients with Kawasaki disease
Arch Dis Child
Kawasaki disease
Coron Artery Dis
Nationwide surveillance of Kawasaki disease in Japan, 1984 to 1993
Pediatr Infect Dis J
Arthritis in Kawasaki syndromefurther characterization
Arthritis Rheum Suppl
Soluble interleukin-2 receptors in children with Kawasaki syndrome
Arthritis Rheum
[Serum interleukin-2 receptor in patients with Kawasaki disease]
Arerugi
Cited by (79)
Diagnosis, Progress, and Treatment Update of Kawasaki Disease
2023, International Journal of Molecular SciencesAnkle and Foot: Focus on Inflammatory Disease
2023, Seminars in Musculoskeletal RadiologyDemographic and clinical features of pediatric vasculitis: a single-center study
2023, ARP RheumatologyImpact of Kawasaki disease on juvenile idiopathic arthritis in real-world patients: A population-based cohort study
2022, Frontiers in ImmunologyExtracardiovascular injury complications in Kawasaki disease
2022, Pediatric Investigation
Rae S. M. Yeung is supported by a New Investigator Award from the Arthritis Society of Canada and the Canadian Institute of Health Research.